BACKGROUND: Mutations in the tumor suppressor gene p53 are associated with neoplasia in ulcerative colitis, but little is understood of their significance in Crohn's disease (CD). PURPOSE: To explore p53 expression as a marker of neoplasia in CD patients. METHODS: This is a retrospective review of CD patients who underwent p53 IHC staining in our center between 1995 and 2003. The p53 status was correlated to the presence and grade of neoplasia at the time of staining and in subsequent follow-up. RESULTS: Fourteen CD patients had p53 assessment: eight were p53 positive and six were p53 negative. Seven of eight p53+ had dysplasia (six LGD, one HGD); one of six p53-had dysplasia (LGD) (P = 0.03). Four p53+ patients with follow-up had persistent dysplasia and two had progression to a higher grade. Three p53- patients with follow-up remained free of dysplasia. CONCLUSIONS: This limited study shows that p53 over expression in CD patients is associated with dysplasia that may progress to a higher grade of neoplasia over time.
BACKGROUND: Mutations in the tumor suppressor gene p53 are associated with neoplasia in ulcerative colitis, but little is understood of their significance in Crohn's disease (CD). PURPOSE: To explore p53 expression as a marker of neoplasia in CDpatients. METHODS: This is a retrospective review of CDpatients who underwent p53 IHC staining in our center between 1995 and 2003. The p53 status was correlated to the presence and grade of neoplasia at the time of staining and in subsequent follow-up. RESULTS: Fourteen CDpatients had p53 assessment: eight were p53 positive and six were p53 negative. Seven of eight p53+ had dysplasia (six LGD, one HGD); one of six p53-had dysplasia (LGD) (P = 0.03). Four p53+ patients with follow-up had persistent dysplasia and two had progression to a higher grade. Three p53- patients with follow-up remained free of dysplasia. CONCLUSIONS: This limited study shows that p53 over expression in CDpatients is associated with dysplasia that may progress to a higher grade of neoplasia over time.
Authors: H Uesugi; H Mitomi; M Sada; H Takahashi; K Kobayashi; M Igarashi; T Katsumata; A Ihara; Y Ohtani; S Ikeda; I Okayasu Journal: Scand J Gastroenterol Date: 1999-11 Impact factor: 2.423
Authors: W R Connell; J E Lennard-Jones; C B Williams; I C Talbot; A B Price; K H Wilkinson Journal: Gastroenterology Date: 1994-10 Impact factor: 22.682
Authors: N Harpaz; A L Peck; J Yin; I Fiel; M Hontanosas; T R Tong; J N Laurin; J M Abraham; B D Greenwald; S J Meltzer Journal: Hum Pathol Date: 1994-10 Impact factor: 3.466
Authors: B D Greenwald; N Harpaz; J Yin; Y Huang; Y Tong; V L Brown; T McDaniel; C Newkirk; J H Resau; S J Meltzer Journal: Cancer Res Date: 1992-02-01 Impact factor: 12.701
Authors: Joel R Pekow; Urszula Dougherty; Reba Mustafi; Hongyan Zhu; Masha Kocherginsky; David T Rubin; Stephen B Hanauer; John Hart; Eugene B Chang; Alessandro Fichera; Loren J Joseph; Marc Bissonnette Journal: Inflamm Bowel Dis Date: 2011-05-06 Impact factor: 5.325
Authors: Ramanarao Dirisina; Rebecca B Katzman; Tatiana Goretsky; Elizabeth Managlia; Navdha Mittal; David B Williams; Wei Qiu; Jian Yu; Navdeep S Chandel; Lin Zhang; Terrence A Barrett Journal: Gastroenterology Date: 2011-05-27 Impact factor: 22.682
Authors: Karoline Horisberger; Thomas Ried; Timo Gaiser; Daniela Hirsch; Darawalee Wangsa; Yuelin J Zhu; Yue Hu; Daniel C Edelman; Paul S Meltzer; Kerstin Heselmeyer-Haddad; Claudia Ott; Peter Kienle; Christian Galata Journal: Clin Cancer Res Date: 2018-07-02 Impact factor: 12.531
Authors: Monique M Gerrits; Min Chen; Myrte Theeuwes; Herman van Dekken; Marjolein Sikkema; Ewout W Steyerberg; Hester F Lingsma; Peter D Siersema; Bing Xia; Johannes G Kusters; C Janneke van der Woude; Ernst J Kuipers Journal: Cell Oncol (Dordr) Date: 2011-02-17 Impact factor: 6.730